Preimplantation genetic testing for aneuploidy (PGT-A) is being used increasingly around the world to improve embryo selection and clinical outcomes per embryo transfer. With a clinical trial confirming the benefits of avoiding the transfer of aneuploid embryos, more data emerging on which embryos with so-called mosaic aneuploidies can be safely transferred and promising data on non-invasive testing, 2020 has seen several important advances. In this webinar, the current state of the art for PGT-A will be reviewed.
This webinar was recorded in December, 2020.
Presenter - Prof. Alan H. Handyside
Working with Prof Lord Robert Winston at the Hammersmith Hospital, London, reported the first pregnancies worldwide following in vitro fertilisation (IVF) and preimplantation genetic diagnosis of inherited disease in 1990. First chairman of the European Society for Human Reproduction and Embryology (ESHRE) Special Interest Group in Reproductive Genetics and co-founder and first chairman of the ESHRE PGD Consortium. Currently, Honorary Professor at the School of Biosciences, University of Kent in Canterbury, UK, ex-President of the International Society for Preimplantation Genetic Diagnosis (PGDIS), President of the International Society for Reproductive Genetics (ISRG) and scientific advisor (genomics) to Vitrolife Sweden AB, Gothenburg, Sweden.